{"entity":{"id":"philogen-s-p-a","kind":"company","name":"Philogen S.p.A.","aka":[],"tldr":"Philogen S.p.A. is a Italy-based biotechnology company running 8 late-stage cancer trials of Onfekafusp alfa and onfekafusp alfa in melanoma, glioma & glioblastoma and basal cell carcinoma.","summary":"Philogen S.p.A., based in Siena, Italy, is a biotechnology company listed as BIT:PHIL. Philogen is a biotechnology company developing targeted cancer therapeutics based on antibodies and small molecules directed at the tumour microenvironment. On ClinicalTrials.gov it is the lead sponsor of 8 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing Onfekafusp alfa and onfekafusp alfa in melanoma, glioma & glioblastoma, basal cell carcinoma and sarcomas. The largest, NCT04443010 (Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma), plans to enrol 226 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.philogen.com"},{"label":"ClinicalTrials.gov: trials led by Philogen S.p.A.","url":"https://clinicaltrials.gov/search?lead=Philogen%20S.p.A."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","glioblastoma","basal-cell-carcinoma","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06284590","nct04733183","nct07227870","nct02938299","nct07227350","nct03567889","nct04443010","nct06336291"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Siena","country":"IT","companyType":"biotech","website":"https://www.philogen.com","ticker":"BIT:PHIL","founded":1996,"stage":"public","investors":[],"funding":[]},"route":"/companies/philogen-s-p-a/","neighbours":{"cancer":[{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"trial":[{"id":"nct06336291","kind":"trial","name":"A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence","route":"/trials/nct06336291/"},{"id":"nct04733183","kind":"trial","name":"Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma","route":"/trials/nct04733183/"},{"id":"nct03567889","kind":"trial","name":"Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients","route":"/trials/nct03567889/"},{"id":"nct07227350","kind":"trial","name":"L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)","route":"/trials/nct07227350/"},{"id":"nct07227870","kind":"trial","name":"L19IL2/TNF in Patients With Basal Cell Carcinoma","route":"/trials/nct07227870/"},{"id":"nct02938299","kind":"trial","name":"Neoadjuvant L19IL2/L19TNF- Pivotal Study","route":"/trials/nct02938299/"},{"id":"nct04443010","kind":"trial","name":"Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma","route":"/trials/nct04443010/"},{"id":"nct06284590","kind":"trial","name":"Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients","route":"/trials/nct06284590/"}],"drug":[{"id":"daromun","kind":"drug","name":"Daromun","route":"/drugs/daromun/"}]}}